| Price and Chart delayed at least 15 mintues. |
|
Price
$ 24.62
|
Change
0.00
|
|
Open
0.00
|
% Change
0.0%
|
|
Prev Close
24.62
|
Volume
NA
|
|
Market Value
40 bil
|
P/E Ratio
18.8
|
|
Bid
17.60
|
EPS
1.31
|
|
Ask
0.00
|
Dividend
0.26
|
|
High
0.00
|
Yield
1.1
|
|
Low
0.00
|
Shares Out
1.63 bil
|
|
52wk High
25.29
|
52wk Low
11.97
|
|
Industry: Drug Manufacturers - Major
|
|
Sector: Healthcare
|
SGP Profile
The Company discovers, develops and manufactures pharmaceuticals for three customer markets - human prescription, animal health, and consumer.
Schering-Plough Corp.
2000 Galloping Hill Road
Kenilworth, NJ 07033
Phone: (908) 298-4000
Fax: (908) 298-7082
Web Site: www.schering-plough.com
SGP Wires Headlines
|
|
| 07.02.09 |
|
Final Glance: Pharmaceuticals companies
|
|
| 07.02.09 |
|
Midday Glance: Pharmaceuticals companies
|
|
| 07.02.09 |
|
Early Glance: Pharmaceuticals companies
|
|
| 07.01.09 |
|
Final Glance: Pharmaceuticals companies
|
|
| 07.01.09 |
|
UPDATE 1-Bayer sues Teva in U.S. for patent infringement
|
More SGP From Wires Headlines >
Forbes.com on SGP RSS
No news found in the past 30 days.SGP Press Releases
|
|
| 07.01.09 |
|
Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa |
|
| 06.29.09 |
|
Schering-Plough Schedules Conference Call Webcast for 2009 Second Quarter Earnings |
|
| 06.26.09 |
|
SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous... |
|
| 06.23.09 |
|
Schering-Plough Declares Quarterly Dividends on Common Shares and Mandatory Convertible... |
|
| 06.17.09 |
|
The New York Yankees' Mark Teixeira, National Foundation For Cancer Research, and the Makers of... |
More SGP Press Releases >
SGP Ratios & Returns
| Price-to-sales |
2.2 |
| Return on Equity |
29.0 |
| Operating Margin |
5.5 |
| Profit Margin |
13.3% |
More SGP Ratios & Returns >
SGP Financials
| Sales |
$18.238 bil |
| Profits |
$2.418 bil |
| Assets |
$27.718 bil |
| Employees |
51000.0 |
|
|
|
Schering-Plough is ranked # 227 on the 2009 Forbes 2000 List
|
|
Thomson / IBES Earnings Estimates on SGP
Accounting Risk
Buy/Hold/Sell Analysis
Forbes Investment Guru Commentary on SGP
RSS News Feed on SGP
|
A D V E R T I S E M E N T
|